Collegium Pharmaceutical Inc (COLL)
Official siteHEALTHCARE • DRUG MANUFACTURERS - SPECIALTY & GENERIC • NASDAQ
Market Cap: $786.83M
Last updated: Nov 17, 2026 at 11:04 AM ET
Collegium Pharmaceutical Inc (COLL) Financials: Revenue, Profit and Cash Flow
Collegium Pharmaceutical reported revenue of $780.57M for the fiscal year ended Dec 31, 2025, up 23.6% from the year before. That year, net income was $62.87M with a net margin of 8.1%, operating cash flow was $329.32M and free cash flow was $327.58M. The quarter ended Sep 30, 2026 had revenue of $216.34M and net income of $21.76M.
Revenue and Margins
The operating margin was 23.0% in the fiscal year ended Dec 2025. Over the 9 years to Dec 2025, revenue grew from $1.71M, a compound annual rate of 97.5%.
| Fiscal year | Revenue | Growth | Gross margin | Operating margin | Net margin |
|---|---|---|---|---|---|
| Dec 2025 | $780.57M | +23.6% | 59.3% | 23.0% | 8.1% |
| Dec 2024 | $631.45M | +11.4% | 59.8% | 26.9% | 11.0% |
| Dec 2023 | $566.77M | +22.2% | 57.5% | 29.5% | 8.5% |
| Dec 2022 | $463.93M | +67.6% | 45.2% | 7.2% | -5.4% |
| Dec 2021 | $276.87M | -10.7% | 54.4% | 6.4% | 25.8% |
| Dec 2020 | $310.02M | +4.5% | 58.0% | 18.1% | 8.6% |
| Dec 2019 | $296.70M | +5.8% | 34.7% | -8.0% | -7.7% |
| Dec 2018 | $280.41M | +884.7% | 40.9% | -7.4% | -14.0% |
| Dec 2017 | $28.48M | +1564.3% | 90.9% | -264.9% | -262.9% |
| Dec 2016 | $1.71M | N/A | 87.6% | -5498.7% | -5504.1% |
Income Statement
In the fiscal year ended Dec 2025, net income fell 9.1% from the year before. In the quarter ended Sep 2026, net income fell 30.9% from the same quarter a year earlier.
Annual
| Line item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $780.57M | $631.45M | $566.77M | $463.93M | $276.87M | $310.02M | $296.70M | $280.41M | $28.48M | $1.71M |
| Cost of revenue | $317.31M | $254.10M | $240.60M | $254.44M | $126.25M | $130.18M | $193.66M | $165.68M | $2.60M | $213.00K |
| Gross profit | $463.26M | $377.34M | $326.17M | $209.49M | $150.62M | $179.84M | $103.04M | $114.74M | $25.88M | $1.50M |
| Research and development | $0 | $0 | $0 | $3.98M | $9.45M | $9.77M | $10.34M | $8.66M | $8.57M | $14.95M |
| Operating income | $179.64M | $169.90M | $166.96M | $33.32M | $17.63M | $56.23M | -$23.75M | -$20.68M | -$75.45M | -$94.08M |
| Net income | $62.87M | $69.19M | $48.16M | -$25.00M | $71.52M | $26.75M | -$22.72M | -$39.13M | -$74.86M | -$94.18M |
| EBITDA | $409.98M | $343.04M | $323.62M | $180.54M | $89.95M | $126.75M | -$8.27M | $90.22M | -$74.89M | -$93.46M |
Quarterly
| Line item | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $216.34M | $199.88M | $193.52M | $205.45M | $209.36M | $188.00M | $177.76M | $181.95M | $159.30M | $145.28M | $144.92M | $149.75M |
| Gross profit | $125.42M | $110.29M | $117.25M | $128.38M | $129.17M | $108.38M | $97.32M | $98.29M | $96.79M | $90.81M | $91.46M | $94.63M |
| Operating income | $28.72M | $3.70M | $30.90M | $60.76M | $62.09M | $35.10M | $21.69M | $38.11M | $34.84M | $47.47M | $49.47M | $61.69M |
| Net income | $21.76M | -$15.05M | $14.50M | $16.96M | $31.51M | $11.98M | $2.42M | $12.54M | $9.34M | $19.61M | $27.71M | $31.94M |
Balance Sheet
As of Dec 2025, total debt of $809.33M exceeded cash and equivalents by $578.07M.
Annual
| Line item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Total assets | $1.66B | $1.66B | $1.14B | $1.17B | $692.08M | $643.84M | $306.30M | $291.25M | $135.57M | $162.02M |
| Current assets | $691.41M | $482.26M | $537.60M | $419.99M | $315.54M | $277.89M | $255.72M | $237.51M | $133.48M | $158.57M |
| Cash and equivalents | $231.25M | $70.56M | $238.95M | $173.69M | $186.43M | $174.12M | $170.02M | $146.63M | $118.70M | $153.22M |
| Total liabilities | $1.36B | $1.43B | $947.88M | $979.29M | $489.15M | $457.81M | $218.87M | $199.66M | $31.49M | $27.11M |
| Short-term debt | $29.00M | $93.54M | $183.33M | $162.50M | $48.35M | $47.49M | $3.83M | $1.64M | $1.48M | $2.67M |
| Long-term debt | $780.33M | $787.90M | $483.84M | $538.45M | $201.63M | $209.59M | $7.67M | $9.86M | $0 | $1.48M |
| Shareholder equity | $301.68M | $228.84M | $195.43M | $194.84M | $202.93M | $186.03M | $87.43M | $91.58M | $104.08M | $134.91M |
Quarterly
| Line item | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total assets | $2.10B | $2.14B | $1.65B | $1.66B | $1.61B | $1.59B | $1.63B | $1.66B | $1.64B | $1.05B | $1.11B | $1.14B |
| Total liabilities | $1.80B | $1.82B | $1.34B | $1.36B | $1.33B | $1.36B | $1.40B | $1.43B | $1.40B | $836.80M | $892.08M | $947.88M |
| Cash and equivalents | $144.80M | $129.47M | $268.65M | $251.10M | $150.10M | $117.35M | $96.19M | $70.56M | $38.96M | $172.89M | $228.61M | $238.95M |
| Shareholder equity | $296.44M | $311.91M | $312.42M | $301.68M | $274.81M | $232.21M | $234.43M | $228.84M | $234.28M | $216.58M | $222.17M | $195.43M |
Cash Flow
In the fiscal year ended Dec 2025, free cash flow was 99.5% of operating cash flow. Share repurchases came to 7.7% of it.
Annual
| Line item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | $329.32M | $204.98M | $274.75M | $124.23M | $103.56M | $93.94M | $27.78M | $169.39M | -$67.02M | -$75.05M |
| Capital expenditures | $1.74M | $1.65M | $461.00K | $1.62M | $1.94M | $5.55M | $6.44M | $5.48M | $990.00K | $477.00K |
| Free cash flow | $327.58M | $203.33M | $274.29M | $122.61M | $101.61M | $88.40M | $21.34M | $163.91M | -$68.01M | -$75.53M |
| Dividends paid | N/A | N/A | $9.10M | N/A | $12.71M | $7.33M | N/A | N/A | $736.00K | $24.57M |
| Share repurchases | $25.10M | $60.02M | $75.00M | $14.06M | $47.86M | $0 | $0 | $30.00K | N/A | N/A |
| Investing cash flow | -$63.53M | -$287.76M | -$70.81M | -$573.69M | -$1.94M | -$373.77M | -$6.44M | -$24.35M | -$990.00K | -$2.98M |
| Financing cash flow | -$110.25M | -$60.60M | -$140.18M | $436.72M | -$89.30M | $286.47M | $2.04M | -$117.20M | $33.48M | $135.56M |
Quarterly
| Line item | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | $86.54M | $71.32M | $57.11M | $123.05M | $78.44M | $72.44M | $55.40M | $84.64M | -$9.00M | $67.40M | $61.94M | $73.34M |
| Capital expenditures | $277.00K | $496.00K | $270.00K | $689.00K | $188.00K | $65.00K | $798.00K | $570.00K | $244.00K | $270.00K | $568.00K | $164.00K |
| Free cash flow | $86.26M | $70.83M | $56.84M | $122.36M | $78.25M | $72.37M | $54.60M | $84.07M | -$9.24M | $67.13M | $61.37M | $73.17M |
Frequently Asked Questions About COLL
What is Collegium Pharmaceutical's annual revenue?
Collegium Pharmaceutical reported revenue of $780.57M for the fiscal year ended Dec 31, 2025.
How fast is Collegium Pharmaceutical's revenue growing?
Revenue was up 23.6% for the fiscal year ended Dec 31, 2025 compared with the year before. The compound annual revenue growth rate over 3 years was 18.9%.
Is Collegium Pharmaceutical profitable?
Yes. Collegium Pharmaceutical reported net income of $62.87M for the fiscal year ended Dec 31, 2025, with a net margin of 8.1%.
How much free cash flow does COLL generate?
For the fiscal year ended Dec 31, 2025, operating cash flow of $329.32M minus capital expenditures of $1.74M produced free cash flow of $327.58M.
How much debt does Collegium Pharmaceutical have?
The balance sheet dated Dec 31, 2025 reported long-term debt of $780.33M, short-term debt of $29.00M and cash and equivalents of $231.25M.
COLL pages: Overview, Earnings, Forecast, Financials, Valuation, Competitors